Holen Sie sich die Stockscreener-App
24.14
3.56%
-0.89
Vorhandelsmarkt:
23.94
-0.20
-0.83%
Schlusskurs vom Vortag:
$25.03
Offen:
$24.51
24-Stunden-Volumen:
25.87M
Relative Volume:
0.69
Marktkapitalisierung:
$5.59B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
46.24
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
-10.19%
1M Leistung:
+14.14%
6M Leistung:
-33.04%
1J Leistung:
-62.28%
1-Tages-Spanne:
$23.26
$24.89
1-Wochen-Bereich:
$23.26
$30.39
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
24.14 | 5.79B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
16.64 | 51.87B | 29.85B | 776.90M | 4.35B | 0.2408 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.25 | 41.70B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.02 | 40.34B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
74.34 | 32.26B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
579.54 | 24.69B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Is Hims & Hers Health Inc (HIMS) a Bargain After 3.6% Drop? GF V - GuruFocus
Hims & Hers Health Options Spot-On: On May 13th, 165.49K Contracts Were Traded, With 1.24 Million Open Interest - Moomoo
S&P 500 Valuation Looks Stretched as Inflation Reprices Rate-Cut Odds - Investing.com
(HIMS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
HIMS Stock Crashes Overnight After Brutal Q1 — But An Investor Says Novo, Lilly Deals Could Make It ‘Netflix Of Healthcare’ - Stocktwits
BofA Cuts Hims & Hers Price Target as Mixed Quarter Resets Street Expectations - AOL.com
Hims & Hers breaks further below key technical level after earnings miss - MSN
Hims & Hers breaks further below key technical level after earnings miss (HIMS:NYSE) - Seeking Alpha
Hims & Hers Health: The Market Is Selling The Wrong Quarter (NYSE:HIMS) - Seeking Alpha
PPI Report April 2026: How Inflation Data Is Moving HIMS, CEG, and PLUG Stock Today - TradingKey
HIMS Maintained by B of A Securities -- Price Target Lowered to $30 - GuruFocus
Compounded GLP-1 write-down drives Hims & Hers Health stock lower by 14.10% - Traders Union
Hims & Hers Health (HIMS) Reports Q1: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Hims & Hers Earnings Call Balances Pain With Growth - TipRanks
Hims & Hers winning bullish views despite Q1 miss - MSN
This Week's Healthcare Earnings: Novo, Hims And More - Law360
Hims & Hers Health: The Real Story Begins (NYSE:HIMS) - Seeking Alpha
JPMorgan Cuts Hims & Hers Price Target as GLP-1 Shift Reshapes the Growth Story - AOL.com
Health Care Roundup: Market Talk - WSJ
Hims & Hers Just Lost $92 Million Trying to Join the GLP-1 Craze - inc.com
CVS Health Corp Stock (CVS) Closed Up by 3.31% on May 12: A Full Analysis - TradingKey
Hims & Hers Health (HIMS) Faces Analyst Scrutiny Amid Revenue Ou - GuruFocus
Hims & Hers stock plunges after Q1 miss: Is the GLP-1 pivot enough to fuel a recovery? - MSN
Hims & Hers winning bullish views despite Q1 miss (HIMS:NYSE) - Seeking Alpha
Hims & Hers Health Is Maintained at Overweight by JP Morgan - Moomoo
HIMS Faces Stock Drop After Weak Q1 Earnings Report - GuruFocus
Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery? - MarketBeat
Hims & Hers shares plunge after surprise loss and revenue miss - TradingView
HIMS Maintained by JP Morgan -- Price Target Lowered to $33.00 - GuruFocus
Why Hims & Hers Health Stock Just Crashed - AOL.com
Hims & Hers Health Posts Mixed Q1 Amid Weight-Loss Product 'Noise': Analysts - Benzinga
Hims & Hers Stock Plunges Post Q1 Earnings Miss, Gross Margin Down - Yahoo Finance
Biggest stock movers Tuesday: PLUG, HIMS, ASTS, QUBT, and more - Seeking Alpha
Hims & Hers shares plummet on first quarter earnings miss - Yahoo Finance
Hims & Hers Health Stock (HIMS) Sinks on Dismal Q1 Earnings and Outlook; Here’s What Analysts Are Saying - TipRanks
HIMS Faces Unexpected Losses Amid Strategic Shift - GuruFocus
Why Hims & Hers Health (HIMS) Is Up 6.9% After GLP-1 Pivot Spurs Q1 Loss And Guidance Hike - Yahoo Finance
Hims & Hers plunges as branded weight-loss drug pivot hits results - KFGO
HIMS Reiterated by BTIG -- Rating Remains Neutral - GuruFocus
Intel, Micron, Quantum Computing, AST SpaceMobile, Hims & Hers, GameStop, and More Movers - Barron's
Hims & Hers stock sinks after quarterly loss, sales miss - AOL.com
Hims & Hers Health, Inc. Stock 12‑Month Price Target Raised to $27.51, Implies 6% Downside - TradingView
HIMS Stock Plummets After Q1 Loss and Weak Guidance - GuruFocus
Hims & Hers (HIMS) Shares Slide After Surprise First-Quarter Loss - Yahoo Finance
Hims & Hers: I See No New Red Flags (NYSE:HIMS) - Seeking Alpha
Hims & Hers is going bigger on weight loss treatments - GuruFocus
Hims and Hers stock sees BTIG maintain Neutral after Q1 miss - Investing.com
Why is Hims & Hers stock being hammered today? By Investing.com - Investing.com Nigeria
Hims & Hers Health, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Hims & Hers Health, Inc. (NYSE:HIMS) Q1 2026 Earnings Call Transcript - Insider Monkey
TD Cowen raises Hims and Hers stock price target to $25 on guidance - Investing.com
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.25%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):